Skip to Content


In the US, Efavirenz (efavirenz systemic) is a member of the drug class NNRTIs and is used to treat HIV Infection, Nonoccupational Exposure and Occupational Exposure.

US matches:

UK matches:



ATC (Anatomical Therapeutic Chemical Classification)


CAS registry number (Chemical Abstracts Service)


Chemical Formula


Molecular Weight


Therapeutic Categories

Antivirals for systemic use - Antiviral agent

Treatment of HIV infection

Non-nucleoside reverse transcriptase inhibitor (NNRTI)

Chemical Name

(S)-6-chloro-4-(cyclopropyletynyl)-1,4-dihydro-4-(trifluorometyl)-2H-3,1-benzoxazin-2-one (WHO, Ph. Int.)

Foreign Names

  • Efavirenzum (Latin)
  • Efavirenz (German)
  • Éfavirenz (French)
  • Efavirenz (Spanish)

Generic Names

  • Efavirenz (OS: BAN, JAN)
  • Éfavirenz (OS: DCF)
  • DMP 266 (DuPont Merck) (IS)
  • L 743726 (DuPont Merck) (IS)
  • Efavirenz (PH: Ph. Int. 7, USP 41)
  • Efavirenzum (PH: Ph. Int. 7)

Brand Names


BANBritish Approved Name
DCFDénomination Commune Française
ISInofficial Synonym
JANJapanese Accepted Name
OSOfficial Synonym
PHPharmacopoeia Name
Rec.INNRecommended International Nonproprietary Name (World Health Organization)

Further information on drug naming conventions: International Nonproprietary Names.

Important Notice: The international database is in BETA release. This means it is still under development and may contain inaccuracies. It is not intended as a substitute for the expertise and judgement of your physician, pharmacist or other healthcare professional. It should not be construed to indicate that the use of any medication in any country is safe, appropriate or effective for you. Consult with your healthcare professional before taking any medication.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.